Lindsay Hoyle asked (10 February 2009: Column 1936W) what steps will be taken to ensure that the arrangements for patients to pay privately for treatments that the NHS will not pay for do not act as a disincentive for pharmaceutical companies to develop cheaper treatments.Dawn Primarolo: The 2009 Pharmaceutical Price Regulation Scheme (PPRS) recognised that…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2025 All rights reserved LaingBuisson 
